IL162293A0 - Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules - Google Patents
Formulation and dosage form for increasing oral bioavailability of hydrophilic macromoleculesInfo
- Publication number
- IL162293A0 IL162293A0 IL16229302A IL16229302A IL162293A0 IL 162293 A0 IL162293 A0 IL 162293A0 IL 16229302 A IL16229302 A IL 16229302A IL 16229302 A IL16229302 A IL 16229302A IL 162293 A0 IL162293 A0 IL 162293A0
- Authority
- IL
- Israel
- Prior art keywords
- formulation
- dosage form
- oral bioavailability
- hydrophilic macromolecules
- increasing oral
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229920002521 macromolecule Polymers 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34300501P | 2001-12-19 | 2001-12-19 | |
PCT/US2002/041031 WO2003053401A2 (en) | 2001-12-19 | 2002-12-18 | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162293A0 true IL162293A0 (en) | 2005-11-20 |
Family
ID=23344273
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16229302A IL162293A0 (en) | 2001-12-19 | 2002-12-18 | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
Country Status (14)
Country | Link |
---|---|
US (1) | US20030198619A1 (xx) |
EP (1) | EP1465592A2 (xx) |
JP (1) | JP2005519884A (xx) |
KR (1) | KR20040066177A (xx) |
CN (1) | CN1606432A (xx) |
AU (1) | AU2002359793B2 (xx) |
CA (1) | CA2471096A1 (xx) |
HU (1) | HUP0402451A3 (xx) |
IL (1) | IL162293A0 (xx) |
MX (1) | MXPA04006026A (xx) |
NO (1) | NO20043028L (xx) |
NZ (1) | NZ533060A (xx) |
WO (1) | WO2003053401A2 (xx) |
ZA (1) | ZA200405655B (xx) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7658938B2 (en) | 1999-02-22 | 2010-02-09 | Merrion Reasearch III Limited | Solid oral dosage form containing an enhancer |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
JP2005533084A (ja) * | 2002-06-28 | 2005-11-04 | アルザ・コーポレーシヨン | 液体の有効成分の製剤を含んでなりかつ膨張可能な浸透圧組成物によりその放出を制御する経口の投薬形態 |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2005011630A2 (en) * | 2003-07-31 | 2005-02-10 | Alza Corporation | Permeation-resistant osmotic engine and dosage form for controlled release of a liquid active agent formulation |
NZ546148A (en) | 2003-09-26 | 2009-05-31 | Alza Corp | Drug coating providing high drug loading and methods for providing the same |
DE602004006763T2 (de) * | 2003-09-26 | 2008-02-07 | Alza Corp., Mountain View | Darreichungsform zur kontrollierten Freisetzung einer Formulierung mit aktivem Mittel und Verfahren zur Herstellung der Darreichungsform |
CA2540045A1 (en) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Dosage form for controlled release of an active agent formulation |
US20070259033A1 (en) * | 2003-09-26 | 2007-11-08 | Evangeline Cruz | Controlled release formulations exhibiting an ascending rate of release |
JP5105578B2 (ja) | 2003-11-05 | 2012-12-26 | サーコード バイオサイエンス インコーポレイテッド | 細胞接着のモジュレーター |
US7563460B2 (en) * | 2004-02-26 | 2009-07-21 | Med Five, Inc. | Enteric coated oral pharmaceutical to erode kidney stones |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
NZ553263A (en) * | 2004-07-19 | 2010-06-25 | Biocon Ltd | Insulin-oligomer conjugates, formulations and uses thereof |
AR050043A1 (es) | 2004-08-03 | 2006-09-20 | Novartis Ag | Metodos para mejorar la biodisponibilidad y composicion farmaceutica para trastornos cardiovasculares |
US20080254108A1 (en) * | 2004-08-23 | 2008-10-16 | Mark Rosenberg | Formulations and Methods for Modulating Satiety |
US8541026B2 (en) | 2004-09-24 | 2013-09-24 | Abbvie Inc. | Sustained release formulations of opioid and nonopioid analgesics |
CA2960117C (en) | 2005-05-17 | 2018-01-30 | Sarcode Bioscience Inc. | Lfa-1 antagonists for the treatment of eye disorders |
EP2007397B1 (en) | 2006-04-07 | 2013-07-24 | Merrion Research III Limited | Solid oral dosage form containing an enhancer |
KR20140018439A (ko) | 2006-05-02 | 2014-02-12 | 프로테우스 디지털 헬스, 인코포레이티드 | 환자 주문형 치료법 |
JP5916277B2 (ja) * | 2006-10-25 | 2016-05-11 | プロテウス デジタル ヘルス, インコーポレイテッド | 摂取可能な制御活性化識別子 |
EP1927350A1 (en) * | 2006-11-24 | 2008-06-04 | Novartis AG | Methods for improving bioavailability of a renin inhibitor |
US8858432B2 (en) | 2007-02-01 | 2014-10-14 | Proteus Digital Health, Inc. | Ingestible event marker systems |
EP2111661B1 (en) | 2007-02-14 | 2017-04-12 | Proteus Digital Health, Inc. | In-body power source having high surface area electrode |
US8115618B2 (en) | 2007-05-24 | 2012-02-14 | Proteus Biomedical, Inc. | RFID antenna for in-body device |
DK2170930T3 (da) | 2007-06-04 | 2012-11-05 | Synergy Pharmaceuticals Inc | Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2009054914A1 (en) | 2007-10-19 | 2009-04-30 | Sarcode Corporation | Compositions and methods for treatment of diabetic retinopathy |
US8802156B2 (en) | 2007-11-14 | 2014-08-12 | Laboratorios Farmacéuticos Rovi, S.A. | Pharmaceutical forms for the release of active compounds |
WO2009139817A2 (en) | 2008-04-15 | 2009-11-19 | Sarcode Corporation | Crystalline pharmaceutical and methods of preparation and use thereof |
TW200950799A (en) | 2008-05-07 | 2009-12-16 | Merrion Res Iii Ltd | Compositions of GnRH related compounds and processes of preparation |
JP2011522828A (ja) | 2008-06-04 | 2011-08-04 | シナジー ファーマシューティカルズ インコーポレイテッド | 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト |
US20110009715A1 (en) | 2008-07-08 | 2011-01-13 | David O' Reilly | Ingestible event marker data framework |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
TWI478712B (zh) | 2008-09-30 | 2015-04-01 | Astellas Pharma Inc | 釋控性醫藥組成物 |
SG172846A1 (en) | 2009-01-06 | 2011-08-29 | Proteus Biomedical Inc | Ingestion-related biofeedback and personalized medical therapy method and system |
US8609409B2 (en) | 2009-06-04 | 2013-12-17 | Clemson University | Methods and compositions for cell culture platform |
US8481067B2 (en) * | 2009-06-04 | 2013-07-09 | Clemson University Research Foundation | Methods for promoting the revascularization and reenervation of CNS lesions |
US8680182B2 (en) | 2009-06-04 | 2014-03-25 | Clemson University Research Foundation | Methods for promoting the revascularization and reenervation of CNS lesions |
US8378105B2 (en) | 2009-10-21 | 2013-02-19 | Sarcode Bioscience Inc. | Crystalline pharmaceutical and methods of preparation and use thereof |
TWI517050B (zh) | 2009-11-04 | 2016-01-11 | 普羅托斯數位健康公司 | 供應鏈管理之系統 |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
WO2011120033A1 (en) | 2010-03-26 | 2011-09-29 | Merrion Research Iii Limited | Pharmaceutical compositions of selective factor xa inhibitors for oral administration |
JP5849947B2 (ja) | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
JP5849946B2 (ja) | 2010-03-29 | 2016-02-03 | アステラス製薬株式会社 | 放出制御医薬組成物 |
TWI557672B (zh) | 2010-05-19 | 2016-11-11 | 波提亞斯數位康健公司 | 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2819234A1 (en) | 2011-01-07 | 2012-07-12 | Merrion Research Iii Limited | Pharmaceutical compositions of iron for oral administration |
WO2015112603A1 (en) | 2014-01-21 | 2015-07-30 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
US9756874B2 (en) | 2011-07-11 | 2017-09-12 | Proteus Digital Health, Inc. | Masticable ingestible product and communication system therefor |
CN103841979B (zh) * | 2011-07-19 | 2019-01-11 | 百深有限责任公司 | 作为改善非抗凝血的硫酸多糖的口服制剂的添加剂的吸收促进剂 |
BR112014001397A2 (pt) | 2011-07-21 | 2017-02-21 | Proteus Biomedical Inc | dispositivo, sistema e método de comunicação móvel |
KR102326359B1 (ko) | 2012-05-18 | 2021-11-12 | 제넨테크, 인크. | 고농도 모노클로날 항체 제제 |
CA2879982C (en) | 2012-07-25 | 2020-09-01 | Sarcode Bioscience Inc. | Lfa-1 inhibitor and polymorph thereof |
EP2958577A2 (en) | 2013-02-25 | 2015-12-30 | Synergy Pharmaceuticals Inc. | Guanylate cyclase receptor agonists for use in colonic cleansing |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
US11744481B2 (en) | 2013-03-15 | 2023-09-05 | Otsuka Pharmaceutical Co., Ltd. | System, apparatus and methods for data collection and assessing outcomes |
CN103463290A (zh) * | 2013-09-10 | 2013-12-25 | 南方医科大学 | 一种防治胃溃疡的口服原位凝胶剂 |
US9606054B2 (en) * | 2013-09-30 | 2017-03-28 | Advantest Corporation | Methods, sampling device and apparatus for terahertz imaging and spectroscopy of coated beads, particles and/or microparticles |
JP6661531B2 (ja) | 2013-10-10 | 2020-03-11 | シナジー ファーマシューティカルズ インコーポレイテッド | オピオイド誘発性機能障害の治療に有用なグアニル酸シクラーゼのアゴニスト |
US10084880B2 (en) | 2013-11-04 | 2018-09-25 | Proteus Digital Health, Inc. | Social media networking based on physiologic information |
BR112016016623B1 (pt) * | 2014-01-21 | 2022-02-01 | Bpsi Holdings, Llc | Revestimentos de película de liberação imediata que contêm glicerídeos de cadeia média e substratos revestidos os mesmos |
JP2017512757A (ja) * | 2014-02-24 | 2017-05-25 | ウリゲン ファーマシューティカルズ、インコーポレイテッド | 経口投与するためのペントサンポリ硫酸塩の組成物および使用の方法 |
US9417181B2 (en) | 2014-05-08 | 2016-08-16 | Advantest Corporation | Dynamic measurement of density using terahertz radiation with real-time thickness measurement for process control |
WO2016120378A1 (en) | 2015-01-29 | 2016-08-04 | Novo Nordisk A/S | Tablets comprising glp-1 agonist and enteric coating |
US20180318336A1 (en) * | 2015-05-27 | 2018-11-08 | Vanguard Therapeutics, Inc. | Pentosan polysulfate sodium for the treatment of sickle cell disease |
CN105131083B (zh) * | 2015-07-30 | 2018-07-10 | 陕西师范大学 | 具有血管紧张素转化酶抑制活性的扁杏仁肽及其制备方法 |
EP3402804A1 (en) | 2016-01-11 | 2018-11-21 | Synergy Pharmaceuticals Inc. | Formulations and methods for treating ulcerative colitis |
CN105919974B (zh) * | 2016-04-28 | 2019-03-01 | 中国医药集团总公司四川抗菌素工业研究所 | 鲑鱼降钙素磷脂复合物及其脂质纳米粒和制备方法 |
CN111772582A (zh) | 2016-07-22 | 2020-10-16 | 普罗秋斯数字健康公司 | 可摄入事件标记的电磁感测和检测 |
WO2021050320A1 (en) * | 2019-09-09 | 2021-03-18 | Harrow Ip, Llc | Pharmaceutical compositions comprising heparinoids and methods for preparing thereof |
GB2625490A (en) * | 2021-01-27 | 2024-06-19 | D&D Pharmatech Inc | Pharmaceutical composition comprising large physiologically active substance and excipient |
CN118019522A (zh) * | 2021-09-07 | 2024-05-10 | D&D制药技术股份有限公司 | 包含大的生理活性物质和赋形剂的药物组合物 |
CN116509794B (zh) * | 2023-05-19 | 2024-03-15 | 上海市肿瘤研究所 | 一种口服温敏凝胶制剂及其制备方法与应用 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2799241A (en) * | 1949-01-21 | 1957-07-16 | Wisconsin Alumni Res Found | Means for applying coatings to tablets or the like |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
NL271831A (xx) * | 1960-11-29 | |||
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US3865108A (en) * | 1971-05-17 | 1975-02-11 | Ortho Pharma Corp | Expandable drug delivery device |
US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) * | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4002173A (en) * | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
US4077407A (en) * | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4207893A (en) * | 1977-08-29 | 1980-06-17 | Alza Corporation | Device using hydrophilic polymer for delivering drug to biological environment |
US4200098A (en) * | 1978-10-23 | 1980-04-29 | Alza Corporation | Osmotic system with distribution zone for dispensing beneficial agent |
US4627850A (en) * | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
US4627851A (en) * | 1984-10-26 | 1986-12-09 | Alza Corporation | Colonic-therapeutic delivery system |
US4915949A (en) * | 1987-07-13 | 1990-04-10 | Alza Corporation | Dispenser with movable matrix comprising a plurality of tiny pills |
US5024842A (en) * | 1988-04-28 | 1991-06-18 | Alza Corporation | Annealed coats |
US5160743A (en) * | 1988-04-28 | 1992-11-03 | Alza Corporation | Annealed composition for pharmaceutically acceptable drug |
US5006346A (en) * | 1988-04-28 | 1991-04-09 | Alza Corporation | Delivery system |
US4931285A (en) * | 1988-04-28 | 1990-06-05 | Alza Corporation | Aqueous based pharmaceutical coating composition for dosage forms |
US5126142A (en) * | 1989-07-18 | 1992-06-30 | Alza Corporation | Dispenser comprising ionophore |
US5324280A (en) * | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
US5190765A (en) * | 1991-06-27 | 1993-03-02 | Alza Corporation | Therapy delayed |
US5252338A (en) * | 1991-06-27 | 1993-10-12 | Alza Corporation | Therapy delayed |
US5424289A (en) * | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
US5633011A (en) * | 1994-08-04 | 1997-05-27 | Alza Corporation | Progesterone replacement therapy |
DE69842121D1 (de) * | 1997-12-10 | 2011-03-17 | Cyclosporine Therapeutics Ltd | Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen |
US6551613B1 (en) * | 1998-09-08 | 2003-04-22 | Alza Corporation | Dosage form comprising therapeutic formulation |
US6174547B1 (en) * | 1999-07-14 | 2001-01-16 | Alza Corporation | Dosage form comprising liquid formulation |
AU765909C (en) * | 1998-12-17 | 2004-09-23 | Alza Corporation | Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings |
AU1881600A (en) * | 1998-12-23 | 2000-07-31 | Alza Corporation | Dosage forms comprising porous particles |
US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
US6491949B2 (en) * | 2000-01-14 | 2002-12-10 | Osmotica Corp. | Osmotic device within an osmotic device |
WO2002076404A2 (en) * | 2001-03-23 | 2002-10-03 | Protarga, Inc. | Fatty alcohol drug conjugates |
-
2002
- 2002-12-18 US US10/324,154 patent/US20030198619A1/en not_active Abandoned
- 2002-12-18 MX MXPA04006026A patent/MXPA04006026A/es unknown
- 2002-12-18 CA CA002471096A patent/CA2471096A1/en not_active Abandoned
- 2002-12-18 IL IL16229302A patent/IL162293A0/xx unknown
- 2002-12-18 HU HU0402451A patent/HUP0402451A3/hu unknown
- 2002-12-18 NZ NZ533060A patent/NZ533060A/xx unknown
- 2002-12-18 AU AU2002359793A patent/AU2002359793B2/en not_active Ceased
- 2002-12-18 KR KR10-2004-7009469A patent/KR20040066177A/ko not_active Application Discontinuation
- 2002-12-18 CN CNA028255577A patent/CN1606432A/zh active Pending
- 2002-12-18 WO PCT/US2002/041031 patent/WO2003053401A2/en active IP Right Grant
- 2002-12-18 EP EP02794356A patent/EP1465592A2/en not_active Withdrawn
- 2002-12-18 JP JP2003554160A patent/JP2005519884A/ja active Pending
-
2004
- 2004-07-13 NO NO20043028A patent/NO20043028L/no not_active Application Discontinuation
- 2004-07-15 ZA ZA200405655A patent/ZA200405655B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20030198619A1 (en) | 2003-10-23 |
HUP0402451A2 (hu) | 2005-07-28 |
CA2471096A1 (en) | 2003-07-03 |
AU2002359793A1 (en) | 2003-07-09 |
EP1465592A2 (en) | 2004-10-13 |
JP2005519884A (ja) | 2005-07-07 |
AU2002359793B2 (en) | 2007-06-14 |
NZ533060A (en) | 2006-03-31 |
WO2003053401A2 (en) | 2003-07-03 |
HUP0402451A3 (en) | 2008-04-28 |
NO20043028L (no) | 2004-09-20 |
MXPA04006026A (es) | 2005-03-31 |
WO2003053401A3 (en) | 2004-01-15 |
ZA200405655B (en) | 2005-08-15 |
CN1606432A (zh) | 2005-04-13 |
KR20040066177A (ko) | 2004-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL162293A0 (en) | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules | |
HUP0303800A3 (en) | Pharmaceuticals and dosage forms of epothilones for oral administration | |
PL356358A1 (en) | Solid dosage form of someticone for oral administration | |
IL166489A (en) | Oral dosage form in single-dose administration containing at least two layers for the administration and use of flipridone | |
AU2002357012A1 (en) | Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof | |
EP1383518A4 (en) | ORAL DELIVERY OF MACROMOLECULES | |
HUP0400281A3 (en) | Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation | |
HK1070285A1 (en) | Pharmaceutical dosage form of amorphous nelfinavirmesylate | |
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
HK1072898A1 (en) | Galenic microparticulate oral formulation for delayed and controlled release of pharmaceutical active principles | |
AU2002216701A1 (en) | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs | |
HRP20040545A2 (en) | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability | |
EP1372392A4 (en) | ORAL DOSAGE FORM CONTAINING NICOTINE | |
IL162666A0 (en) | A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof | |
HUP0500638A2 (en) | Flashmelt oral dosage formulation | |
HUP0400386A3 (en) | Tablet comprising cetirizine and pseudoephedrine and its use for preparation of pharmaceutical compositions | |
IL154268A0 (en) | Improved solid pharmaceutical dosage formulation of hydrophobic drugs | |
IL162510A0 (en) | Pharmaceutical suspension for oral administration | |
AU2002317063A (en) | Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same | |
AU2002317063A1 (en) | Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same | |
IL155855A0 (en) | Pharmaceutical formulation of gepirone for oral administration | |
EP1361866A4 (en) | EMULSIONS AS SOLID DOSAGE FORMS FOR ORAL ADMINISTRATION | |
HUP0401371A3 (en) | Pharmaceutical formulation containing an ltb4 antagonist and process for its preparation | |
AU2002348105A1 (en) | Oral dosage forms for improving the bioavailability of therapeutic agents | |
LT1925308T (lt) | Kietas peroralinis aripiprazolio farmacinis preparatas ir jo gavimo būdai |